Towards Curative Outcomes in Canine Hemangiosarcoma

This nationwide clinical trial aims to achieve curative outcomes for 400 dogs with splenic hemangiosarcoma—a highly aggressive cancer that disproportionately affects  older, large breed dogs. Despite aggressive treatment, more than 50% of affected  dogs die within 6 months due to metastatic spread. The research will leverage  genomic insights to: (1) identify molecular biomarkers for prognosis; (2) define  genomic subgroups that may benefit from specific anticancer drugs; and (3) develop  new therapeutic approaches to prevent cancer spread. This approach follows the  roadmap used in transforming childhood leukemia from a fatal diagnosis to a commonly cured disease.

Relevance to PWDs: PWDs are at risk for hemangiosarcoma. This study could  transform treatment approaches for this devastating disease that currently has poor outcomes. The innovative approach could lead to personalized treatment protocols  and potentially curative therapies for affected dogs.

Co-sponsored with the AKC Canine Health Foundation, Grant Number: 02946

RESEARCHERS

Chand Khanna, DVM, PhD; Ethos Discovery

Amount: $10,000